Other,increases
Other,ddtSprays
Other,Targeting
Other,highestSe
Other,tangshanPeople
Other,Using
Other,dcisDiagnosis
Other,currentUtilizedHistopathologicBiomarkers
Other,HADS
Other,chlorambucilPlatinum
Other,cytologicalExamination
Other,breast
Biopsy,tissueBiopsy
Other,medianAge
Other,significantDifference
Other,mass
Other,fiveYearRfsrate
Other,figures
Other,shapes
Radiotherapy,neoadjuvantChemotherapyGroups
Other,lungChanges
Other,learning
Other,cutoffValues
Other,Wilm
Radiotherapy,locoregionalRadiotherapy
Other,methylationStatus
Other,article
Other,specificGroups
Other,random-samplingMethod
Other,diagnosticUncertainty
Other,usStandardization
Other,detectionMethod
Other,results
Other,analyses
SNVs,sharedSnvs
Hereditary,distinctiveGeneticModifications
Other,methodsDesign
Toxicity,number
Other,furtherUnderstanding
Other,BPE
Other,counseling
Other,totalOf121Patients
Other,erEvaluation
Other,challenge
Other,finding
Survival,comparisons10-yearSurvival
Long-term,theirLong-termSurvival
Other,those
Other,dysregulation
Other,mostNondestructiveTests
Other,targetingFxyd3-mediatedPathway
Other,Resurgery
Other,data
Other,ecchymosis
Other,percecnt
Other,kinds
Other,Applications
Other,group1
Other,virtualReality
Other,trastuzumab
Resistance,endocrineResistance
Other,signalIntensity
Hazard,coxProportionalHazardRegressionModels
Hazard,risk
Other,edition
Other,cardiacTroponins
Other,dual-phaseContrast
Other,symptomaticWomen
Technique,imagingTechnique
Other,stigmatization
Presentations,rarePresentations
Other,molecularBasis
Other,recentDevelopments
Other,mastectomizedWomen
Other,diagnosticRole
Other,dictionaryLearning
Other,aim
Other,advancedAnalysis
Other,cpgIslands
Other,186Pathology-provenS
Other,differentials
Other,undifferentiatedNeoplasticCells
Other,multiplexAssay
Other,chineseExpertGroup
Other,infiltrationSimilar
Other,variousNon-pharmacologicalAdjuvantTherapies
Other,PFS
Other,networkOutput
Other,breastCancerStudies
Other,MRI
Other,commonCancerTypes
Other,detectionofBreastCancer
Technique,controlGroup
Other,appropriateSequencing
Other,studies
Other,presence
Other,microfluidicPlatform
Regulatory,molecularRegulatoryNetworks
Other,post-nacBpeLevels
Advantage,tumorSizethePositivity
Other,medianTime
Other,signatures
Other,Co-existence
Other,tissues
Care,intervention
Survival,survivalRate
Other,agreement
Cytology,fine-needleAspirationCytology
Other,sensor
Other,theirTissues
Other,functionalAssessments
Other,comparisons
Other,adherence
Other,rnaKnockdown
Other,binaryLogisticRegressionModels
Other,futureClinicalStudies
Other,repair
Other,axillarySurgery
Other,lowCtnLevels
Other,icgFluorescenceMethod
Other,fastRate
Other,genes
Other,paTreatment
Other,program
Other,suutaneousEcchymosis
Other,conditions
Other,Mechanisms
Hazard,breastCancerRisk
Other,volume
Other,racialDisparity
Other,complexConsulting
Other,Data
Other,practitionersKnowledgeable
Other,increasedRonExpression
Other,risks
Other,147Patients
RNAs,RNAs
Other,advancedStage
Other,promoterMethylationStatus
Other,restoration
Other,extensiveExploration
Other,novelty
Other,two-yearStudy
Other,occurrence
Other,surgery
Other,interview
Other,improvedDetection
Other,manyComputerVisionApplications
Other,miR-511
Other,symptomaticHeartFailure
Other,factor-1Scores
Other,female
Other,literature
Other,tissueDiagnosis
Other,furtherResearch
Hereditary,11HereditaryBreastCancerGenes
Survival,flowRate
Other,commonComplaint
Other,dissection
Other,476Years
Other,detection
Other,NAC
Other,predictors
Care,primaryCareProvider
Other,therapies
Other,esr1-activatingMutations
Other,examination
Other,Cryopreservation
Other,Associations
Strategy,short-termStrategy
Paraneoplastic,paraneoplasticAntibodyPanel
Mechanism,pdgfs/pdgfrsAxis
Other,expressionLevels
Other,Survival
Subtype,subtype
Hazard,riskFactors
Other,humanEpidermalGrowthFactorReceptor2ReceptorStatus
Other,microarrayAnalysis
Other,emphasis
Other,premenopausalPatients
Other,smallerMyeloperoxidase
Membrane,membraneTypeMannoseReceptor
Other,axillaryDissection
Other,geneExpressionLevel
Vulnerability,nsaidsExposure
Other,oneMutation
Other,age-basedScreeningPrograms
Other,andfemales
Other,backgroundTrastuzumab
Other,histopathologicalreports
Other,its
Vulnerability,nsaidExposure
Other,historyPhysicalExamFindings
Other,breastCancerCases
Other,Acupuncture
Other,otherInotherTertiaryCentres
Other,Mammographic
Other,accuracy
Cytology,urgentCytology
Other,glut1Expression
Other,CNVs
Other,recurrentWords
Other,improvedUnderstanding
Other,manyBreastCancerPatients
Other,dnaMethylation
Other,Comparisons
Other,cytohistologicalComparisons
Other,ET
Other,selectiveBinding
Other,diagnosis
Other,associations
Neuromas,breastNeuromas
Other,TBR
Other,stagingSystems
Other,sialicAcidExpression
Image,imageQuality
Other,menopausalHormoneTherapy
Other,breastCancerMetastasis
Other,scope
Other,measures
Other,furtherTissue
Other,Nek6
Other,performed
Image,image
Other,firstSteps
Variants,variants
Other,0-5Years
Other,Probes
Other,700
Other,accumulatingResults
Other,adjustedProportion
Other,chinesePublic
Other,ourBreastCancerPatients
Other,optimalCutoffValues
Other,extremeLearningMachineClassification
Other,femalePatients
Other,Univariate
Other,miR-34s
Other,Recurrences
Other,Ki67
Other,diagnosticEvaluation
Exposure,coxModel
Other,yearRfsrate
Other,magneticResonanceImaging
Other,she
Other,drugBinding
Technique,2-groupRandomizedControlTrial
Other,Information
Other,epigeneticAberrations
Other,undergone
Other,408
Other,p
Survival,survivalRates
Other,clearcellPlatform
Other,aberrances
Signature,medianInterval
Other,youngMen
Other,we
Other,interference
Symptom,bestAvailableEvidence
Hazard,coxHazardRegressionModels
Other,osteopontin-basedProbe
Other,twoImagingIndexes
Other,bpeLevels
Other,morcFamilyCw-typeZincFinger4Overexpression
Other,pathologicalSpecimen
Other,mammograms
Other,symptoms
Other,women'sPersonalGoals
Other,theory
Other,P
Signature,signature
Other,characterization
Other,undergoing
Assays,reporterAssays
Other,leucocytes
Other,concerns
Other,10Mg/kg
Other,screeningPrograms
Other,molecularAnalyses
Other,measurements
Other,zero-inflatedPoissonRegression
Other,state-of-the-artAlgorithms
Other,cylindricalGeometries
Parameters,parameters
Other,Mammography
Other,level
Other,cancerFibroblasts
Other,This
Other,Obesity
Other,Demographics
Other,their
Other,decrease
Other,proteinExpression
Other,evidence-basedRecommendations
Other,trastuzumab/pertuzumab/taxane
Other,LVI
Other,tolerabilitytheApatinib
Susceptibility,tertiarySexualHealthCenters
Other,rnaOligonucleotides
Other,double-maintenanceTherapy
Other,adhesionProtein-1
Other,SVM-BRC
Other,propagation-basedPhase-contrast
Other,hybridCultures
Other,pathologists'Awareness
Other,significance
Other,proposedCovariance-basedSpdMatrices
Other,muchFocus
Other,multipleSolicitations
Other,all
Other,therapeuticTarget
Other,twenty-twoPatients
Other,imaging
Other,capabilities
Other,theirParaffin-embeddedTissues
Other,greatPromise
Care,theory-basedIntervention
Other,time
Other,molecularChanges
Other,relationship
Other,newBilateralIntrapulmonaryNodules
Other,properties
Other,baselineSt-2Level
Other,propensityScoreMatchingAnalysis
Other,enhancerRegions
Other,Belgium
Other,the
Other,support
Other,firstOrganisedRound
Other,mutationEvents
Other,available
Other,preclinicallyTams
Other,cohortStudy
Other,treatments
Variants,pathogenicVariants
Other,options
Biopsy,sentinelNodeBiopsy
Other,parameterUncertainty
Other,mastectomies
Other,development
Susceptibility,cancerSusceptibilityGenes
Hazard,multivariateCoxProportionalHazardRegressionAnalysis
Other,previousCervicalCancerScreening
Other,population
Susceptibility,nippleInvolvement
Other,circulatingSolubleRankl
Vulnerability,vulnerability
Care,cancerCareCenter
Other,1
Other,prognosticValue
Other,FOXC1
Care,careProvider
Other,luciferaseReporterAssay
Other,eralphaTranscription
Other,77
Immunohistochemical,immunohistochemicalAnalysis
Signature,objectiveResponseRate
Other,flankingCgi
Other,bilateralMastectomies
Factor,factorAnalysis
Other,omission
Other,breastMetastases
Other,902Percecnt
Other,unbiasedRnaSequenceAnalysis
Other,doses
Other,RRM2
Other,post-NAC
Other,means
Other,long-termUse
Other,robustSynthesisMethods
Other,selectedStandardTreatments
Other,occultBreastTumors
Other,caDetection
Other,periods
Other,third
Other,description
Other,dynamicContrast
Other,currentMeans
Other,carbohydrateRestriction
Other,Diseases
Overexpression,Overexpression
Other,delay
Other,essentialRole
Other,threeDifferentClusters
Other,surgicalOutcomes
Other,carbonDioxideLaserTechnology
Other,morphologicalDifferentials
RNAs,longNoncodingRnas
Other,erImmunohistochemistry
Other,years
Other,tumorCells
Other,contribution
Other,research
Other,guidedImagery
Other,treatmentRegimens
Guidelines,internationalGuidelines
Other,It
Other,smallProportion
Other,medicalStatus
Strategy,risk-stratifiedScreeningStrategy
Other,mixedMethodsDesign
Other,importantPotential
Other,materialDetection
Cell,cancerStemCellHypothesis
Quantification,multidimensionalScaling
Other,7581StageI/iiaCases
Hazard,Risk
Other,troponins
Survival,metabricTrainingSet
Other,factors
Other,differentDetectionRates
Other,subset
Other,282Patients
Other,existence
Presentations,rareClinicalPresentations
Other,networks
Other,postmenopausalPatient
Other,breastCancerScreening
Other,recentDanishCohortStudy
Other,occurringCancers
Other,8155Patients
Other,novelTargetedTherapeuticOptions
Membrane,membraneTypeMr
Other,occurring
Other,resultsDiagnosed
Correlation,correlationCoefficient
Other,haveCenterstage
Other,significantIncrease
Other,microfluidicChips
Other,non-sentinelLymphNode
Other,circRNAs
Other,twoChlorambucilPlatinum
Other,effectiveness
Other,exercise
Other,drugDeliveryStrategies
Other,itsRole
Other,pearson'sR
Other,Cells
Other,oestrogenReceptorAlpha
Other,supplements
Other,comparisonCohort
Other,differentPrognosis
Other,markers
Other,mostStigmatization
Other,cross-sectionalStudy
Other,large-scaleStudies
Other,77Patients
Other,morc4Silencing
Other,futureInterventions
Other,quadrantectomy
Other,AMD3100
Radiotherapy,anthracyclineChemotherapyAgents
Other,matchedHealthyTissues
Other,clinicalDepression
Other,inclusion
Other,12331Non-nsaidUsers
Other,fisherAnalysis
Other,lesion
Other,shallowCnn
City,almatyCity
Other,them
Other,Residents
Symptom,cell-killingEffect
Radiotherapy,radiotherapy
Other,hundreds
Other,quality
Other,Familiarity
Other,Researchers
Other,ctcIsolationTechniques
Other,clinicalPicture
Other,OR
Other,recentEpigenomeStudies
Hazard,coxHazardRegressionAnalysis
Other,caloricRestriction
Other,inhibited
Other,newSpecificMarkers
Other,ctnLevels
Other,personalDecision-making
Other,lowClassificationAccuracies
Other,ca15-3Detection
Other,wavelengthConsistencyIndex
Other,deep-CNN
Other,nano-genosensor
Other,complication
Other,knockdown
Other,They
Other,probe
Other,comparison
Other,95PercecntConfidenceIntervals
Other,treatmentProcesses
Other,20
Other,nondestructiveTests
Toxicity,numberVariants
Survival,theirSurvival
Other,samples
Other,first-lineTreatment
Other,novelMethod
Other,contrastAgents
Other,regressionModels
Other,positiveChanges
Other,substantialImprovements
Other,collectedSignatures
Image,appearance
Other,suchStandardization
Other,surgicalImplantationReconstruction
Neoadjuvant,neoadjuvantTreatment
SNVs,SNVs
Other,specificEralpha-targetedProbe
Other,mab1e3
Other,importantRole
Other,38-year-oldFemale
Other,secondLargestHmo
Other,hugeVolumes
Other,interpretation
Other,fibroblastsAdjacent
Other,screeningTools
Other,type
Toxicity,increasingNumber
Other,wordCloud
Other,noninvasiveImaging
Other,160Patients
Other,56Patients
Other,deepLearning
Exposure,excellentPerformance
Other,opticalAbsorptions
Other,detailedRoles
Hazard,anticipatedOutcome
Other,platform
Other,paper
Other,prevention
Other,use
Other,scan
Other,therapy
Other,Access
Other,multivariate
Surgeries,complexSurgeries
Other,prospectiveStudies
Other,sevenWomen
Other,Immunohistochemistry
Other,preoperativeUnderstanding
Symptom,effect
Other,directEffects
Image,commonAdultCancers
Signature,three-lncrnaSignature
Subtype,oneSpecificSubtype
Other,classifiers
Other,necessity
Other,diagnoses
Other,most
Hereditary,geneticChanges
Parameters,pharmacokineticParameters
Other,combinedAnalysis
Symptom,hyperglycemia
Other,Findings
Other,sixCirculatingMirnas
Other,need
Other,role
Other,22Deaths
Other,histologicalExamination
Other,framework
Other,54BreastCancerPatients
Other,sentinelNodes
Other,switch
Other,sox9NucleusEntry
Other,speed
Other,they
Other,postAssessment
Cell,CellLines
Susceptibility,healthCenters
Other,frequentMutations
Other,35-64Years
Hazard,lowerCumulativeHazardRates
Other,murineMonoclonalAntibodies
Other,knowledgeSummaries
Biopsy,stereotacticWire-guidedBiopsy
Other,traditionalPredictors
Other,Isolation
Other,screening
Resistance,netvizzApplication
Membrane,combinedPanel
Other,pD1542yMissenseMutation
Other,histoneModifications
Other,12331Users
Other,insight
Other,decreasedBpe
Other,40
Other,ourResults
Other,tissue
Hazard,increasedRisk
Other,resonanceImaging
Other,428BreastCancerPatients
Other,msotImaging
Other,12-15Percecnt
Care,healthcareUtilization
Other,70-year-oldWoman
Other,kaplan-meierCurves
Other,proposedMethod
Strategy,publicHealthCareSystem
Other,lymphedemaseventyPatients
Other,aptamerMf3
Signature,responseRate
Other,mastectomy
Other,feasibleCtcIsolationTechniques
Other,syndromes
Other,familySupport
Other,obstetricians
Other,outcomes
Other,algorithm
Radiotherapy,chemotherapy
Other,DSCAM-AS1
Other,craniotomy
Mechanism,statisticalAssociation
Other,z-test
Other,186S
Susceptibility,greaterthanorequalto10PercecntDecline
Other,Mutations
Parameters,similarExperimentalParameters
Other,multigenePanels-with
Other,poorerPrognosis
Other,ssdnaAptamerMf3
Other,newerDrugDeliveryStrategies
Other,rnaSequenceAnalysis
Other,theResulting
Other,groups
Other,NLR
Other,intelligentTechniques
Other,mostPretermBirth
Other,Disease
Other,recommendations
Protocols,treatmentProtocols
Other,increase
Hazard,decreasedRisk
Other,newTreatmentRegimens
Technique,cancerControlPlanning
Other,enforcedExpression
Strategy,nirFluorescenceImagingSystem
Other,megakaryocytes
Other,traumaticNeuroma
Other,15Percecnt
Other,issues
Biopsy,slnBiopsy
Other,hospitalCohort
Other,mechanisms
Other,recurrence-free-survival
Other,mostPatients
Other,overexpression
Other,comprehensiveSearch
Vulnerability,estrogenicExposure
Other,stage
Other,proposedAlgorithm
Other,microRNAs
Other,manyFeatures
Other,thepresence
Hazard,hazardRates
Other,Referrals
Other,3ClinicopathologicalFactors
Other,frequentCancer
Other,st-2Level
Other,towaveletFilter
Other,MicroRNAs
Other,BRCAs
Other,receptorActivator
Other,currentFollow-up
Other,adjuvantEndocrineHormonalTherapy
Other,overallMediumSecondTumor-freeTime
Tumor,tumorNippleDistance
Other,archivedFormalin-fixedParaffin-embeddedTissue
Other,solubleSt-2Level
Mechanism,contraceptiveUse
Other,additionalInformation
Other,determining
Other,Cases
Other,novelNavigationSurgery
Other,levels
Other,youngMalePatients
Other,coverageRates
Membrane,antibodyPanel
Other,DCR
Other,little
Other,9398
Other,respondents
Other,simulatedBreastCancer
Other,twoScales
Other,primaryTumours
Other,surgicalExcision
Variants,single-nucleotideVariants
Other,late-stageCancerDiagnosis
Other,usefulness
Risk,commonCause
Other,smallMoleculeInhibitors
Vivo,fluorescenceImagingExVivo
Other,macrophages
Other,target
Other,aromataseInhibitor-inducedBoneLoss
Survival,breastCancer-specific10-yearSurvival
Other,49Patients
Other,remarkableImprovements
Other,decreases
Other,axillaryLymphNode
Other,osteopontin-750Accumulation
Other,TAMs
Other,conservativeTreatment
Other,cancerAssociatedFibroblasts
Other,emergingTechnology
Biopsy,sentinelLymphNodeBiopsy
Other,relapseRates
Other,0.84
Other,clb-pt-clbProdrug
Other,follow-up
Other,localizedDescription
Resistance,theirApplication
Other,non-standardPromptTreatments
Other,massProduction
Other,peripheralBloodSamples
Other,appropriateInterpretation
Susceptibility,nippleAreolaComplexInvolvement
Other,-916
Other,We
Exposure,model
Other,navigationSurgery
Other,actualIncidence
Exposure,equivalentPerformance
Subtype,definedSubtype
Other,PM
Other,denosumabInjection
Other,differentStudies
Other,multimodalTherapy
Other,mtorInhibitorEverolimus
Other,odds
Other,biomarker
Other,mir-511Overexpression
Other,complaint
Other,highCoverage
Care,care
Other,pi3k/aktSignaling
Other,65-year-oldFemale
Other,Zt/g4-MMAE
Exposure,discovery
Other,SUVmax
Presentations,presentations
Subtype,specificSubtype
Other,tomography
Other,RON
Other,Cholecystectomy
Other,maintainedBreastCancerDatabase
Other,radiationTherapy
Other,esr1Alterations
Exposure,regressionModel
Other,goal
Other,mortality
Other,12404Patients
Other,roles
Other,ultrasound-guidedDiffuseOpticalTomography
Other,firstDiagnosis
Other,microscopicExamination
Other,interplay
Other,tenfoldCross-validationMatthew
Other,AYAs
Other,additionalAnalyses
Other,Depletion
Other,eighthEdition
Other,ORR
Other,components
Other,caseRecords
Other,purpose
Other,progressionDisease
Other,65Patients
Other,treatmentStrategies
Other,weight
Other,pattern
Other,TRPV1
Radiotherapy,chemotherapyHormonalTreatment
Other,segmentationAlgorithm
Other,manyPatients
Image,imageSegmentation
Mechanism,mechanism
Hazard,significantHigherRisk
Other,Kazakhstan
Other,4248BreastCancerPatients
Hazard,surgicalOutcome
Other,esr1Mutations
Other,r
Other,ELISA
Other,precision
Cell,cell
Other,spouse
Other,itsExpressionLevel
Other,10-foldCross-validation
Mechanism,association
Other,a
Other,ageGroups
Other,nek6Expression
Other,sustainedStableDisease
Other,myeloperoxidase
Other,breastCancerPatients
Other,physician
Other,longerPeriods
Other,CNN
Toxicity,considerableNumber
Other,patient'sMedicalHistory
Other,Utilization
Other,Follow-up
Survival,overallMedianSurvival
Other,furtherDevelopment
Other,fewStudies
Advantage,osAdvantage
Other,betterOs
Other,survivalDistributions
Other,recurrence
Neuromas,traumaticBreastNeuromas
Hereditary,multipleGeneticAberrances
Other,induction
Other,status
Other,mammographicImages
Other,pathologicalResults
Other,relatedTranscriptionFactorSox9
Other,jak-statPathway
Other,nsaidUsers
Resistance,resistance
Quantification,successfulQuantification
Other,conventionalTreatmentProcesses
Other,methods
Other,circulatingTumorCells
Other,priorMedicalHistory
Other,massiveCircrnas
Other,irregularHyperintenseLesion
Other,subsequentRadiomics
Other,nanoplatform
Other,suchSymptoms
Symptom,evidence
Other,higherResolution
Other,100000Person-years
Survival,three-yearSurvivalRates
Other,value
Other,ruralCancerHospital
Other,reverseTranscription-quantitativePolymeraseChainReaction
Other,otherData
Other,effects
Other,esr1SomaticAlterations
Other,screeningBehavior
Other,positiveTreatment
Other,comprehensiveResearchData
Other,australianSynchrotron
Care,transcriptionFactorForkheadBoxC1
Other,excision
Other,cells
Other,ourFindings
Other,CLB-Pt-CLB
Other,relapse
Other,largeBreastCancerTissueMicroarray
Other,CEDM
Other,-25-diphenyltetrazoliumBromideAssay
Other,dataAnalytics
Survival,colonyFormation
Other,proteinKinase
Other,ongoingTrials
Other,gonadotropin
Radiotherapy,palliativeChemotherapy
Atypia,nuclearAtypia
Other,total
Contraception,contraceptionUse
Other,sParticipants
Protocols,differentProtocols
Other,481Women
Phenotype,textureFeatures
Other,areas
Other,Validation
Other,estrogenReceptor-alpha
Other,breastImagingModality
Other,focus
Other,lisbonRegion
Strategy,strategy
Other,higherProportion
Other,rate
Other,five
Scans,chestCtScans
Other,allBreastCancerPatients
Other,similarTowaveletFilter
Other,pH
Other,parpInhibitors
Other,alternativeContrast-enhancedScreeningTools
Other,mPatients
Other,microrna-22ExpressionLevels
Signature,lifestyleModification
Other,water
Other,Increase
Other,bromideAssay
Other,collapsing
Other,specificFoodRecommendations
Other,secondTumor
Other,fastingBlood
Other,mabaSurgery
Other,recognizingMethylationStatus
Other,sentinelLymphNode
Other,benchmarkMethod
Other,understanding
Other,analyzing
Other,patient'sTumorBurden
Parameters,morphologicParameters
Other,biocharacter
Other,mastectomiedPatients
Technique,breastCancerControl
Other,22Patients
Radiotherapy,chemotherapyGroups
Signature,interval
Other,filipinoWomen
Other,ourAim
Other,luminalB-likePatients
Other,inhibition
Other,incidence
Other,study
Other,lipidProfiles
Other,optimalCut-offValue
Other,breastScreening
Other,scffbxo22-mediatedKdm4bDegradation
Other,differentialDiagnoses
Other,search
Other,review
Other,breastConservation
Other,advances
Other,non-coverage
Other,breastCancerDetectionMethod
Other,GTPase
Other,radiomics
Protocols,protocols
Other,score
Other,malePatients
Other,directTargetGene
Other,highIndex
Other,prognosticStagingSystems
Susceptibility,identification
Other,biomarkers
Signature,subtype-specificSignature
Other,sparseCoding
Care,multidisciplinaryCare
Other,blackWomen
Other,hypothesis
Other,carrier
Other,breastCancerRelapse
Susceptibility,barcodeMode
Other,controls
Other,late-stage
Other,experts
Exposure,finalMultipleRegressionModel
Other,binding
Other,Results
Other,preoperativeDiagnosis
Other,monteCarloFeatureSelection-basedFeatureSelection-basedComputationalMethod
Other,uniqueEsr1Mutations
Other,yoga
Other,ovarianCancer
TAAs,TAAs
Other,overview
Cytology,breastCancerGenetics
Other,strongContrast
Other,adPatients
Other,Transcripts
Other,mriImaging
Other,betterUnderstanding
Other,prospectiveNestedCase-controlStudy
Other,portugueseInstitute
Hazard,multiresolutionResult
Other,coding
Other,analysis
Other,ourPatient
Other,CTCs
Other,nanocarrier
Other,severalIntelligentTechniques
Other,experience
Other,information
Other,NSAIDs
Other,basis
Hazard,poorerOutcome
Other,CTC
Other,20BreastCancerPatients
Strategy,screeningStrategy
Survival,medianProgression-freeSurvival
Other,Management
Cytology,invasiveLobularHistology
Other,characteristics
Other,DDTs
Other,spdMatrices
Atypia,atypia
Other,postOperativeAssessment
Other,sequencing
Survival,breastSurvival
Other,bio-metal-organicFrameworkCoated
Assays,dual-luciferaseReporterAssays
Other,boneDensity
Other,knowledge
Other,Radiotherapy
Other,disease
Other,mutationRatio
Other,biologicalSubtypes
Syndrome,syndrome
Resistance,physicalActivity
Other,identified
Other,ruralSetting
Radiotherapy,chemotherapyRegimens
Other,vap-1Expression
Other,Individuals
Other,inAssay
Other,plasmaLevels
Other,extramedullaryHaematopoiesis
Other,cutoff
Other,vap-1NegativeStaining
Other,commonCancer
Other,mainMeasures
Other,baselineSolubleSt-2Level
Other,alternativeOption
Exposure,impact
Other,contrast
Other,nonparticipation
Other,lowLevel
Other,SP
Other,management
Other,OP
Other,of121Patients
Other,techniques
Other,ductalCarcinoma
Other,Factors
Other,99Percecnt
Other,individuals
Other,Biomarkers
Other,itsExpression
Other,medianDiagnosisAge
Hazard,result
Other,cancerResearch
Other,MethyLight
Other,staining
Autoantibodies,autoantibodies
Other,smallPopulation
Other,quantitativeRealTimeFluorescencePolymeraseChainReaction
Other,tumorSize
Other,alexnetModels
Other,multi-stimuli-responsiveTheranosticNanoplatform
Other,improvedCancerTreatment
Heterogeneity,heterogeneity
Other,nondestructiveTesting
Other,mStage
Hazard,highestRisk
Other,depletion
Radiotherapy,neoadjuvantChemotherapy
Other,
Other,prognosis
Other,cTn
Other,stageI/iiaCases
Other,aspects
Other,geometries
Other,diseases
Other,2921Posts
Other,Delays
Other,elderlyPatients
Other,Computer
Activities,activities
Hazard,treatmentOutcomePrediction
Other,ratio
Other,volumes
Other,clinicalBreastExamination
Other,antibody-anchoredMagneticBeads
Other,picture
Other,bioimpedanceAnalysis
Other,prediction
Other,mirnaExpressionProfiles
Other,usExaminations
Other,conjugatedEquineEstrogen
Other,ourLiteratureReview
Other,imagingIndexes
Other,moreIntensiveFollow-up
Other,hormone-dependentPositiveBreastCancer
Other,obtainedFeatures
Other,deregulatedMirnas
Other,macrophage-targetedTreatmentStrategies
Other,complexTreatmentAlgorithms
Other,clinicalCharacteristics
Other,method
Other,incidenceRates
Other,advancedBreastCancerBearingMutations
Other,differentiation
Investigation,Investigation
Other,tumor-to-backgroundRatio
Other,responsibleMechanisms
Hazard,clinico-pathologicalRiskFactors
Other,age-matchedSystematicRandom-samplingMethod
Other,952PercecntOfthePostmenopausalWomen
Other,criticalScientificBase
Other,tumorSuppressorFunction
Other,typicalWoman
Other,miRNAs
Other,greatProgress
Other,84Patients
Other,Patients
Other,variousMethods
Other,intensive
Cytology,cytology
Other,clinicians
Other,clinicalRecords
Other,highGlut1Expression
Other,25CaseReports
Other,CGI
Other,higher-qualityImaging
Other,42Patients
Other,Use
Care,rural-basedTertiaryCancerCareCenter
Other,majority
Other,assessment
Other,133BreastCancerCases
Other,mortalityRates
Other,epidemiologicalFeatures
Other,specimen
Other,subtypes
Vulnerability,exposure
Other,Non-linearity
Other,neuroma
Other,convolutionalNeuralNetworks
Other,selectedPatients
Other,intracellularLevel
Parameters,quantitativeParameters
Other,massMedia
Other,rareTumor
Other,simulatedInnerBreastTissue
Other,label-freeDetection
Other,tumor-associatedMacrophages
Other,features
Other,Analysis
Other,eventualKnowledge
Other,age
Other,study'sObjectives
Other,TAM
Other,olderWomen
Hazard,summaryHazardRatios
Other,miR-204-5p
Other,furtherStudies
Other,tumorUptake
Other,neutrophil-to-lymphocyteRatio
Other,Pearson
Other,firstTime
Vulnerability,ddtExposure
Other,experiences
Other,fxyd3Amplification
Other,severalPatients
Other,mammographicBreastCancerScreening
Other,mainObjective
Other,diagnosed
Other,twentyUniqueEsr1Mutations
Survival,survival
Other,case
Other,similarSeriousAdverseEvents
Other,pLessthan
Other,accurateMethod
Other,decreasedExpression
Other,Steps
Other,evaluation
Other,objective
Other,assay
Correlation,expectedInverseCorrelation
Other,otherDietaryRecommendations
Other,observationalStudies
Other,estrogenReceptor
Other,authors
Other,eConcentration
Other,Cell
Other,main
Other,Therapies
Other,highExpression
Other,100Patients
Cytology,histology
Other,alternativeMeans
Other,pathway
Other,1444Women
Other,agonistic/antagonisticBiocharacter
Other,outliers
Biopsy,biopsy
Other,recentStudies
SNPs,SNPs
Other,dscam-as1Expression
Hazard,outcome
Oxidation,oxidationPeakCurrent
Other,patients'Prognosis
Other,standard
Other,it
Sites,keyHypomethylationSites
Other,longerPfs
Other,proportion
Other,percecntConfidenceIntervals
Care,analysisMayAid
Other,availableContrastAgents
Other,606Percecnt
Other,targetedTherapies
Other,multidisciplinaryAssessment
Other,splenicLymphocytes
Other,DAU
Other,coverage
Other,Spouses
Other,causes
Other,otherAgeGroups
Other,ctcCounts
Other,tools
Other,cross-validation
Other,annexinVStaining
Other,lobularCarcinoma
Other,survivalData
Other,nodalMegakaryocytes
Other,theirAbility
Technique,novelPowerfulTechnique
Other,stromalExpression
Other,mainChallenge
Susceptibility,antigenIdentification
Other,summary
Other,methylation
Other,femalePatient
Other,trend
Other,significantAdvances
Membrane,panel
Other,expression
Other,antibodies
Other,material
Correlation,correlation
Other,535941Survivors
Other,highSensitivity
Technique,technique
Other,12SampledWomen
Other,localTherapy
Other,history
Sites,hypomethylationSites
Other,Anthracyclines
Hypomethylation,hypomethylation
Other,China
Other,findings
Other,localRecurrence
Other,treatment
Other,differentialDiagnosis
Other,brainMetastases
Other,monteCarloFeatureFeatureMethod
Other,stableDrug-carrierBinding
Other,1000Patients
Other,linerRegressionAnalysis
Other,accuracyScores
Other,xenograftMice
Acids,omegaFattyAcids
Other,otherSignificantConcerns
Cytology,aspirationCytology
Other,found
Hazard,subjectiveRisk
Other,humanChorionicGonadotropin
Guidelines,guidelines
Radiotherapy,chemotherapyRecommendations
Other,breastExamination
Other,statisticalClassifiers
Advantage,handicap
Other,textureAnalysis
Other,aberrantDnaMethylation
Other,subgroupVariables
Other,suutaneousLymphaticChannels
Radiotherapy,shorterRadiotherapyRegimens
Susceptibility,involvement
Other,immediateUnmetNeed
Other,bloodSamples
Other,transport
Other,separateClassificationModels
Other,suutaneousBreastTumor
Other,Screening
Other,radiomicsScore
Other,133Controls
Other,sensitiveNano-genosensor
Other,anti-ronMonoclonalAntibodyZt/g4-drugMonomethylAuristatinEConjugate
Other,currentAnalysis
Other,earlyBreastCancerDetectionSystems
Other,obstetrician
Phenotype,phenotypeExpression
Other,solicitations
Advantage,goodTolerabilitytheApatinib
Other,SD-CNN
Cytology,surfaceMorphology
Other,conventionalX-rayMammography
Correlation,highCorrelation
Other,tanUsage
Other,cases
Other,clinicalOutcomesDiffer
Other,capillaries
Hazard,cancerRiskPerception
Other,concentrations
Other,reality
Other,She
Exposure,performance
Other,ccsCoverage
Other,synthesisMethods
Other,foodRecommendations
Other,rs5743810ProAllele
Other,mainContribution
Other,numerousGene-expression-basedPrognosticSignatures
Technique,controlTrial
Other,mostWomen
Other,transferLearning
Other,51Patients
Other,therapeuticSequencing
Other,meanTime
Contraception,hormonalContraceptionUse
Other,mutations
Other,fisherDiscriminantAnalysis
Other,conclusionsWomen
Other,limitedLiterature
Other,importance
Parameters,ivimParameters
Other,changes
Other,asymptomaticWomen
Other,vap-1StainingResults
Other,lymphocytes
Other,Identification
Other,secondaryLymphedema
Cytology,intraoperativeScrapeCytology
Other,blood
Other,fibroblasts
Cell,capacitance
Other,promisingSupplements
Other,westernBlotAnalyses
Other,similarPfs
Long-term,differentLong-termSurvival
Resistance,activity
Other,psychologicalAspects
Other,ourTheoreticalAnalysis